Prevalence and impact of long-term use of nicotine replacement therapy in UK stop-smoking services: Findings from the ELONS study

Nicotine and Tobacco Research

Volumn 20, Issue 1, 2018, Pages 81-88

  Shahab, Lion ^a   Dobbie, Fiona ^a   Hiscock, Rosemary ^b   McNeill, Ann ^c   Bauld, Linda ^a  

^a UK CENTRE FOR TOBACCO AND ALCOHOL STUDIES   (United Kingdom)

^b UNIVERSITY OF BATH   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; COTININE; NICOTINE GUM;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; FEMALE; FOLLOW UP; HEALTH SERVICE; HUMAN; LONG TERM CARE; MALE; MIDDLE AGED; NICOTINE REPLACEMENT THERAPY; OUTCOME ASSESSMENT; PATIENT SAFETY; PREVALENCE; PRIORITY JOURNAL; SALIVA ANALYSIS; SMOKING CESSATION; STOP SMOKING SERVICE; UNITED KINGDOM; DRUG THERAPY; EPIDEMIOLOGY; PROCEDURES; PUBLIC HEALTH; SMOKING; SMOKING PREVENTION; UTILIZATION;

ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PREVALENCE; SMOKING; SMOKING CESSATION; SMOKING PREVENTION; TOBACCO USE CESSATION PRODUCTS; UNITED KINGDOM;

EID: 85041345537     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntw258     Document Type: Article

References (50)

1. Beard E, McNeill A, Aveyard P, Fidler J, Michie S, West R. Association between use of nicotine replacement therapy for harm reduction and smoking cessation: a prospective study of English smokers. Tob Control. 2013;22(2):118-122
2. Le Houezec J, McNeill A, Britton J. Tobacco, nicotine and harm reduction. Drug Alcohol Rev. 2011;30(2):119-123
3. Wang D, Connock M, Barton P, Fry-Smith A, Aveyard P, Moore D. 'Cut down to quit' with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis. Health Technol Assess. 2008;12(2):iii-iv, ix
4. Moore D, Aveyard P, Connock M, Wang D, Fry-Smith A, Barton P. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ. 2009;338:b1024
5. Beard E, Fidler J, West R. Is use of nicotine replacement therapy while continuing to smoke associated with increased nicotine intake? Evidence from a population sample. Psychopharmacology (Berl). 2011; 218(3):609-610
6. Shahab L, Beard E, Brown J, West R. Prevalence of NRT use and associated nicotine intake in smokers, recent ex-smokers and longer-term exsmokers. PLoS One. 2014;9(11):e113045
7. Schnoll RA, Patterson F, Wileyto EP, et al. Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial. Ann Intern Med. 2010;152(3):144-151
8. Joseph AM, Fu SS, Lindgren B, et al. Chronic disease management for tobacco dependence: a randomized, controlled trial. Arch Intern Med. 2011;171(21):1894-1900
9. MHRA. MHRA Public Assessment Report. The use of nicotine replacement therapy to reduce harm in smokers. 2010. www. mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON068572. Accessed October 22, 2010
10. MHRA. Report of the Committee on Safety of Medicines Working Group on Nicotine Replacement therapy. 2005. www.mhra.gov.uk/home/groups/pl-a/documents/websiteresources/con2023239.pdf. Accessed April 15, 2016
11. Department of Health. Healthy Lives, Healthy People-A Tobacco Control Plan for England. London, UK: Department of Health; 2011
12. NICE. Tobacco-Harm reduction. 2013. http://publications.nice.org.uk/tobacco-harm-reduction-approaches-to-smoking-ph45. Accessed April 15, 2016
13. Royal College of Physicians. Harm Reduction in Nicotine Addiction: Helping People Who Can't Quit. A Report by the Tobacco Advisory Group of the Royal College of Physicians. London, UK: RCP; 2007
14. Shahab L, Brose LS, West R. Novel delivery systems for nicotine replacement therapy as an aid to smoking cessation and for harm reduction: rationale, and evidence for advantages over existing systems. CNS Drugs. 2013;27(12):1007-1019
15. Fairchild AL, Bayer R, Colgrove J. The renormalization of smoking? E-cigarettes and the tobacco "endgame". N Engl J Med. 2014;370(4):293-295
16. Black A, Beard E, Brown J, Fidler J, West R. Beliefs about the harms of long-term use of nicotine replacement therapy: perceptions of smokers in England. Addiction. 2012;107(11):2037-2042
17. Beard E, McDermott M, McEwen A, West R. Beliefs of stop smoking practitioners in United Kingdom on the use of nicotine replacement therapy for smoking reduction. Nicotine Tob Res. 2012;14(6):639-647
18. Silla K, Beard E, Shahab L. Nicotine replacement therapy use among smokers and ex-smokers: associated attitudes and beliefs: a qualitative study. BMC Public Health. 2014;14:1311
19. Eliasson B, Taskinen MR, Smith U. Long-term use of nicotine gum is associated with hyperinsulinemia and insulin resistance. Circulation. 1996;94(5):878-881
20. Murray RP, Connett JE, Zapawa LM. Does nicotine replacement therapy cause cancer? Evidence from the Lung Health Study. Nicotine Tob Res. 2009;11(9):1076-1082
21. Sims TH, Fiore MC. Pharmacotherapy for treating tobacco dependence: what is the ideal duration of therapy? CNS Drugs. 2002;16(10):653-662
22. Le Strat Y, Rehm J, Le Foll B. How generalisable to community samples are clinical trial results for treatment of nicotine dependence: a comparison of common eligibility criteria with respondents of a large representative general population survey. Tob Control. 2011;20(5):338-343
23. Shiffman S, Sweeney CT. Ten years after the Rx-to-OTC switch of nicotine replacement therapy: what have we learned about the benefits and risks of non-prescription availability? Health Policy. 2008;86(1):17-26
24. Kotz D, Brown J, West R. 'Real-world' effectiveness of smoking cessation treatments: a population study. Addiction. 2014;109(3):491-499
25. Dobbie F, Hiscock R, Leonardi-Bee J, et al. Evaluating Long-term Outcomes of NHS Stop Smoking Services (ELONS): a prospective cohort study. Health Technol Assess. 2015;19(95):1-156
26. Soo-Quee KD, Choon-Huat KG. The use of salivary biomarkers in occupational and environmental medicine. Occup Environ. Med. 2007;64(3):202-210
27. Chen H, Fu Y, Sharp BM. Chronic nicotine self-administration augments hypothalamic-pituitary-adrenal responses to mild acute stress. Neuropsychopharmacology. 2008;33(4):721-730
28. Caggiula AR, Donny EC, Epstein LH, et al. The role of corticosteroids in nicotine's physiological and behavioral effects. Psychoneuroendocrinology. 1998;23(2):143-159
29. Department of Health. Local Stop Smoking Services: Service Delivery and Monitoring Guidance-2011/12. London, UK: Department of Health; 2011
30. Feyerabend C, Russell MA. A rapid gas-liquid chromatographic method for the determination of cotinine and nicotine in biological fluids. J Pharm Pharmacol. 1990;42(6):450-452
31. Bosch JA, de Geus EJ, Veerman EC, Hoogstraten J, Nieuw Amerongen AV. Innate secretory immunity in response to laboratory stressors that evoke distinct patterns of cardiac autonomic activity. Psychosom Med. 2003;65(2):245-258
32. Rohleder N, Wolf JM, Maldonado EF, Kirschbaum C. The psychosocial stress-induced increase in salivary alpha-amylase is independent of saliva flow rate. Psychophysiology. 2006;43(6):645-652
33. Rohleder N, Nater UM. Determinants of salivary alpha-amylase in humans and methodological considerations. Psychoneuroendocrinology. 2009;34(4):469-485
34. Wolf JM, Nicholls E, Chen E. Chronic stress, salivary cortisol, and alphaamylase in children with asthma and healthy children. Biol Psychol. 2008;78(1):20-28
35. Hajek P, McRobbie H, Gillison F. Dependence potential of nicotine replacement treatments: effects of product type, patient characteristics, and cost to user. Prev Med. 2007;44(3):230-234
36. Shahab L, Cummings KM, Hammond D, Borland R, West R, McNeill A. The impact of changing nicotine replacement therapy licensing laws in the United Kingdom: findings from the International Tobacco Control Four Country Survey. Addiction. 2009;104(8):1420-1427
37. Silla K, Beard E, Shahab L. Characterization of long-term users of nicotine replacement therapy: evidence from a national survey. Nicotine Tob Res. 2014;16(8):1050-1055
38. West R, DiMarino ME, Gitchell J, McNeill A. Impact of UK policy initiatives on use of medicines to aid smoking cessation. Tob Control. 2005;14(3):166-171
39. Dockrell M, Morrison R, Bauld L, McNeill A. E-cigarettes: prevalence and attitudes in Great Britain. Nicotine Tob Res. 2013;15(10):1737-1744
40. Brown J, West R, Beard E, Michie S, Shahab L, McNeill A. Prevalence and characteristics of e-cigarette users in Great Britain: findings from a general population survey of smokers. Addict Behav. 2014;39:1120-1125
41. Brown J, West R. Latest trends on smoking in England from the Smoking toolkit study. 2015. www.smokinginengland.info. Accessed April 15, 2016
42. Tønnesen P, Paoletti P, Gustavsson G, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. Eur Respir J. 1999;13(2):238-246
43. Wennike P, Danielsson T, Landfeldt B, Westin A, Tønnesen P. Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up. Addiction. 2003;98(10):1395-1402
44. Fidler JA, Stapleton JA, West R. Variation in saliva cotinine as a function of self-reported attempts to reduce cigarette consumption. Psychopharmacology (Berl). 2011;217(4):587-593
45. Fagerström KO, Tejding R, Westin A, Lunell E. Aiding reduction of smoking with nicotine replacement medications: hope for the recalcitrant smoker? Tob Control. 1997;6(4):311-316
46. Malaiyandi V, Sellers EM, Tyndale RF. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther. 2005;77(3):145-158
47. McEwen A, Hajek P, McRobbie H, West R. Manual of Smoking Cessation. Oxford, UK: Blackwell Publishing; 2006
48. Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol. 1997;29(7):1422-1431
49. Benowitz NL, Jacob P III, Jones RT, Rosenberg J. Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. J Pharmacol Exp Ther. 1982;221(2):368-372
50. Taylor G, McNeill A, Girling A, Farley A, Lindson-Hawley N, Aveyard P. Change in mental health after smoking cessation: systematic review and meta-analysis. BMJ. 2014;348:g1151